4Rego EM, Pandolfi PP. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Semin Hematol, 2001, 38: 54-70.
5Park DJ, Vuong PT, de Vos S, et al. Comparative analysis of genes regulated by PMU RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood, 2003, 102:3727 -3736.
6Rego EM, Wang ZG, Peruzzi D, et al. Role of promyelocytic leukemia (PML)protein in tumor suppression. J Exp Med, 2001, 193: 521-529.
7Gurrieri C, Capodieci P, Bemardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst, 2004, 96: 269-279.
8Bernardi R, Pandolfi PP. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene, 2003, 22: 9048-9057.
9Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signaling. Nature, 2004, 431: 205-211.
10van Wageningen S, Breems-de Ridder MC, Nigten J, et al. Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR alpha. Blood, 2008, 111: 1634-1643.
1Sanz MA,Lo-CocoF.Modern approaches to treating acutepromyelocytic leukemia[J].J Clin Oncol,2011.29(5):495-503.
2Sanz MA,Grimwade D,Tallman MS,et al.Management of acutepromylocytic leukemia:recommendations from an expert panalon behalf of the European Leukemia Net(2)Blood,2009,113(9):1875-1879.
